Immunorizon

Company Overview

Snapshot

Founded in December 2017, Immunorizon operates with 1–10 employees. The company was acquired by Purple Biotech in February 2023, marking a significant exit in the biotechnology sector.

Business overview

Immunorizon is a Health Tech & Life Sciences company focused on developing conditionally activated tumor-restricted T- and NK-cell engagers for cancer therapy. The company's core technology involves extending its pipeline to include tri-specific constructs with additional tumor-associated antigens and diverse engagers targeting both T-cells and NK-cells. Operating within the Pharmaceuticals sector, Immunorizon serves the oncology market with its biotechnology solutions, specifically in drugs discovery and development.

Company Intelligence Q&A

What is Immunorizon's primary focus in cancer therapy?

Immunorizon specializes in developing conditionally activated tumor-restricted T- and NK-cell engagers for cancer therapy, utilizing tri-specific constructs with tumor-associated antigens.

When was Immunorizon founded?

Immunorizon was founded in December 2017.

Which investors participated in Immunorizon's Seed funding round in December 2017?

In December 2017, Immunorizon received Seed funding from M Ventures and ExploreBio.

Which investor participated in Immunorizon's Seed funding round in April 2019?

In April 2019, Immunorizon received Seed funding from M Ventures, an investment that was publicly disclosed.